Enhanced radiosensitivity of CD133+ AT/RT cells after combined treatment with a checkpoint kinases inhibitor and BCL-2 siRNA.
(A) Western blott data showed that the protein levels of BCL-2 in CD133+ AT/RT were significantly upregulated compared with those of CD133−. Treatment of BCL-2 siRNA can efficiently block the protein expression of BCL-2 in CD133+ (upper part). The effect of IR on CD133+ AT/RT cells was significantly improved by DBH alone or DBH in comination with BCL-2 siRNA (lower part). The tumorigenic properties of (B) migration/invasion and (C) tumor colony formation were significantly inhibited in CD133− AT/RT cells treated by DBH alone or DBH combined with BCL-2 siRNA as compared to CD133+ and IR-treated only CD133+ groups. *p<0.05. Data shown are the mean±SD of three experiments.